Congratulations Associate Prof. Dr. Ng Kok Peng and the study team on the First Patient Randomized in Asia-Pacific (APAC) (Second Patient Randomized Globally) for the MOR202C206 study!!
Your hard work and effort are deeply meaningful to UMMC and the nation.
Details of the study: https://clinicaltrials.gov/ct2/show/NCT05065970
Anti-CD38Antibody, BeAHero, CICUMMC, ClinicalInvestigationCentre, ClinicalResearch,
ClinicalResearchinMalaysia, ClinicalTrials, Felzartamab, IgANephropathy, KidneyDisease,
LeaderinClinicalResearch, Malaysia, MOR202C206, Recruiting
